Here are the 10-K annual reports from Odyssey Health Inc (ODYY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ODYY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ODYY filings page.
Odyssey Health, Inc. reported no revenue for the year ended July 31, 2026 and a net loss of $5,729,693, compared with a net loss of $1,742,691 for the year ended July 31, 2025. Net cash used in operating activities was $1,046,358.
At July 31, 2026, cash was $122,361, current liabilities were $12,277,546, and the working capital deficit was $12,129,687. Odyssey disclosed substantial doubt about its ability to continue as a going concern. Convertible notes totaled $4,876,282 in principal, plus accrued interest, including $3,835,282 owed to Mast Hill. Odyssey said it lacked funds to repay the notes at their extended January 31, 2027 maturity. An October 23, 2026 amendment extended all four Mast Hill note maturities and granted limited, one-time waivers for specified defaults.
No products are authorized for commercial distribution. Odyssey says Save-A-Life will be prioritized for further development, while CardioMap development will remain suspended in the near term. Both require FDA clearance or approval before U.S. sales.
Odyssey Health (OTC: ODYY) filed its annual report for the year ended July 31, 2025. The company remains a development-stage medical products business with no FDA-cleared or approved products and no commercial revenue. Management discloses substantial doubt about its ability to continue as a going concern.
As of July 31, 2025, current liabilities were $7,004,421 against current assets of $49,723, resulting in a working capital deficit of $6,954,698. Net loss allocable to common stockholders was $1,742,691 for the period, and the accumulated deficit reached $62,745,837. The aggregate market value of non‑affiliate equity was $1,770,764 as of January 31, 2025, based on a $0.0215 last sale price. Shares outstanding were 99,853,763 as of October 29, 2025.
The portfolio includes CardioMap (heart monitoring) and the Save‑A‑Life choking rescue device; neither has FDA clearance or approval. Due to funding constraints, Save‑A‑Life is prioritized, while CardioMap development is suspended in the near term. The company reports two employees and plans to rely on third‑party partners for manufacturing and distribution if products are cleared.